Comparison Between Neoadjuvant-Chemoradiotherapy Followed by Surgery and Definitive Chemoradiotherapy for Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma (Jcog2305a)
This analysis compares survival outcomes between neoadjuvant chemoradiotherapy and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma.
Key Points
Progression-free survival tended to be better in the neoadjuvant chemoradiotherapy group compared to definitive chemoradiotherapy, but the difference was not significant.
Overall survival rates were nearly identical between the neoadjuvant chemoradiotherapy and definitive chemoradiotherapy groups, suggesting similar efficacy.
Subgroup analyses indicated some patients with specific characteristics had better overall survival outcomes with definitive chemoradiotherapy than neoadjuvant chemoradiotherapy.
The influence of active surveillance and salvage treatment on the outcomes further complicates the comparison between treatment approaches.